Q1 EPS Estimate for Daré Bioscience Reduced by Analyst

Daré Bioscience, Inc. (NASDAQ:DARE) – Stock analysts at Brookline Capital Management cut their Q1 2025 EPS estimates for shares of Daré Bioscience in a report released on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now anticipates that the biotechnology company will post earnings of ($0.68) per share for the quarter, down from their previous estimate of ($0.54). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q2 2025 earnings at ($0.62) EPS and FY2025 earnings at ($2.48) EPS.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02. The business had revenue of ($0.06) million for the quarter, compared to the consensus estimate of $1.00 million.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research note on Tuesday.

Daré Bioscience Price Performance

Shares of DARE stock opened at $2.91 on Thursday. The stock’s fifty day simple moving average is $3.04 and its 200 day simple moving average is $3.28. Daré Bioscience has a one year low of $2.67 and a one year high of $7.56. The firm has a market cap of $25.32 million, a price-to-earnings ratio of -4.93 and a beta of 1.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. AMH Equity Ltd raised its position in Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 50,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares during the last quarter. Renaissance Technologies LLC lifted its position in Daré Bioscience by 6.7% during the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after buying an additional 4,300 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Daré Bioscience during the 4th quarter worth about $52,000. 6.70% of the stock is owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.